Takeda Pharmaceutical (TAK) Change in Intangibles (2018 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly Change in Intangibles of -$310.1 million for Q2 2026, down 65.23% year-over-year from -$891.8 million in Q2 2025, and down 24698.56% quarter-over-quarter from $1.3 million in Q4 2025.
Takeda Pharmaceutical (TAK) Change in Intangibles (2018 - 2026) Analysis & Trends
Takeda Pharmaceutical's Change in Intangibles history runs 9 years deep, the most recent figure standing at -$310.1 million for Q2 2026.
- In Q2 2026, Change in Intangibles fell 65.23% year-over-year to -$310.1 million; the TTM figure through Jun 2026 stood at -$119.9 million (down 116.76% YoY), while the FY2026 annual figure was $5.8 million, down 98.46% from the prior year.
- Change in Intangibles for Q2 2026 stood at -$310.1 million, down from $1.3 million in the prior quarter.
- The five-year high for Change in Intangibles was $1.1 billion in Q1 2025, with the low at -$3.1 billion in Q1 2023.
- The 5-year median for Change in Intangibles is -$139.8 million (2022), against an average of -$351.5 million.
- The sharpest annual moves came in 2023 and 2025: Change in Intangibles tumbled 2108.38% in 2023, then soared 889.3% in 2025.
- Takeda Pharmaceutical's Change in Intangibles stood at -$121.5 million in 2022, then sank by 67.35% to -$203.3 million in 2023, then surged by 62.58% to -$76.1 million in 2024, then soared by 101.66% to $1.3 million in 2025, then tumbled by 24698.56% to -$310.1 million in 2026.
- Business Quant data shows TAK's Change in Intangibles at -$310.1 million in Q2 2026, $1.3 million in Q4 2025, and $189.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -310.09 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Alkermes | 8.02 Bn | 7.37 Bn | 397.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -310.09 Mn |
| Jun 30, 2026 | -310.09 Mn |
| Dec 31, 2025 | 1.26 Mn |
| Dec 31, 2025 | 1.26 Mn |
| Sep 30, 2025 | 188.95 Mn |
| Sep 30, 2025 | 188.95 Mn |
| Jun 30, 2025 | -187.67 Mn |
| Jun 30, 2025 | -187.67 Mn |
| Mar 31, 2025 | 1.05 Bn |
| Mar 31, 2025 | 1.05 Bn |
| Dec 31, 2024 | -76.06 Mn |
| Dec 31, 2024 | -76.06 Mn |
| Sep 30, 2024 | -75.05 Mn |
| Sep 30, 2024 | -75.05 Mn |
| Jun 30, 2024 | -516.21 Mn |
| Jun 30, 2024 | -516.21 Mn |
| Mar 31, 2024 | -133.54 Mn |
| Mar 31, 2024 | -133.54 Mn |
| Dec 31, 2023 | -203.25 Mn |
| Dec 31, 2023 | -203.25 Mn |